Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710.
J Biol Chem. 2019 Sep 20;294(38):13939-13952. doi: 10.1074/jbc.RA119.009091. Epub 2019 Jul 29.
Ionizing radiation (IR) can promote migration and invasion of cancer cells, but the basis for this phenomenon has not been fully elucidated. IR increases expression of glucose-regulated protein 78kDa (GRP78) on the surface of cancer cells (CS-GRP78), and this up-regulation is associated with more aggressive behavior, radioresistance, and recurrence of cancer. Here, using various biochemical and immunological methods, including flow cytometry, cell proliferation and migration assays, Rho activation and quantitative RT-PCR assays, we investigated the mechanism by which CS-GRP78 contributes to radioresistance in pancreatic ductal adenocarcinoma (PDAC) cells. We found that activated α-Macroglobulin (αM*) a ligand of the CS-GRP78 receptor, induces formation of the AKT kinase (AKT)/DLC1 Rho-GTPase-activating protein (DLC1) complex and thereby increases Rho activation. Further, CS-GRP78 activated the transcriptional coactivators Yes-associated protein (YAP) and tafazzin (TAZ) in a Rho-dependent manner, promoting motility and invasiveness of PDAC cells. We observed that radiation-induced CS-GRP78 stimulates the nuclear accumulation of YAP/TAZ and increases YAP/TAZ target gene expressions. Remarkably, targeting CS-GRP78 with C38 monoclonal antibody (Mab) enhanced radiosensitivity and increased the efficacy of radiation therapy by curtailing PDAC cell motility and invasion. These findings reveal that CS-GRP78 acts upstream of YAP/TAZ signaling and promote migration and radiation-resistance in PDAC cells. We therefore conclude that, C38 Mab is a promising candidate for use in combination with radiation therapy to manage PDAC.
电离辐射 (IR) 可促进癌细胞的迁移和侵袭,但这一现象的基础尚未完全阐明。IR 会增加癌细胞表面葡萄糖调节蛋白 78kDa (GRP78) 的表达(CS-GRP78),这种上调与更具侵袭性的行为、放射抗性和癌症复发有关。在这里,我们使用各种生化和免疫方法,包括流式细胞术、细胞增殖和迁移测定、Rho 激活和定量 RT-PCR 测定,研究了 CS-GRP78 如何导致胰腺导管腺癌 (PDAC) 细胞的放射抗性。我们发现,激活的 α-巨球蛋白 (αM*) 是 CS-GRP78 受体的配体,诱导 AKT 激酶 (AKT)/DLC1 Rho-GTPase 激活蛋白 (DLC1) 复合物的形成,从而增加 Rho 的激活。此外,CS-GRP78 以 Rho 依赖的方式激活转录共激活因子 Yes 相关蛋白 (YAP) 和 tafazzin (TAZ),促进 PDAC 细胞的迁移和侵袭。我们观察到,辐射诱导的 CS-GRP78 刺激 YAP/TAZ 的核积累,并增加 YAP/TAZ 靶基因的表达。值得注意的是,用 C38 单克隆抗体 (Mab) 靶向 CS-GRP78 可增强放射敏感性,并通过抑制 PDAC 细胞的迁移和侵袭来提高放射治疗的疗效。这些发现表明,CS-GRP78 在前 YAP/TAZ 信号转导中起作用,并促进 PDAC 细胞的迁移和放射抗性。因此,我们得出结论,C38 Mab 是与放射治疗联合用于治疗 PDAC 的有前途的候选药物。